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Abstract: Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptors, is the most 
recently approved drug for smoking cessation. This paper reviews the outcomes of Phase 2 
and Phase 3 clinical trials that assess the efﬁ  cacy of varenicline in comparison to placebo and 
other smoking cessation pharmacotherapies, ie, sustained-release bupropion (bupropion SR) 
and nicotine transdermal patch. Varenicline has higher abstinence rates than placebo and the 
alternative active treatments at the end of standard regimen treatment periods. Signiﬁ  cantly 
higher abstinence rates were also found with varenicline in comparison to both placebo and 
bupropion SR at the end of a 40-week non-treatment follow-up period. Varenicline typically 
tripled the abstinence rates compared with placebo. In addition, varenicline reduced craving and 
withdrawal symptoms as well as some of the positive experiences associated with smoking to 
a greater extent than placebo, bupropion SR, and nicotine replacement therapy (NRT). These 
ﬁ  ndings are consistent with the proposed agonist/antagonist effects of varenicline. Preliminary 
studies assessing individual variables such as smoking dependency level and smoking rein-
forcement types provide justiﬁ  cation to examine further the effects of varenicline according 
to these individual factors. Outcomes from such research could improve our understanding of 
varenicline’s mechanism of action and could ultimately help clinicians to develop individual-
ized smoking cessation programs. Also, given varenicline’s ability to reduce the reward from 
smoking, it might be helpful to use it before cessation to motivate or prepare smokers for a 
quit attempt.
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Introduction
Globally, cigarette consumption is still increasing, especially within developing 
countries (Mackay et al 2006). Even in the United States (US), where consumption 
has declined, approximately 21% of the adult population were still current smokers 
in 2006 (CDC 2007).
Stopping smoking not only halts, but can reverse the biological damage caused by 
smoking (CDC 2005). For example, stopping smoking has been shown to reduce the 
cardiovascular risk proﬁ  le of former smokers (Terres et al 1994) and has been recog-
nized as an important component of treatment for diseases such as respiratory disease 
(Tønnesen et al 2007) and lung cancer (Hecht 2002). After quitting, the smoking-related 
risk of heart disease mortality can be reduced by up to half (Critchley and Capewell 
2003). Encouraging more smokers to quit would therefore signiﬁ  cantly reduce the high 
morbidity and premature mortality rates currently associated with cigarette smoking 
(American Lung Association 2007).
However, stopping smoking does not come easily. While cigarette smoking is 
often thought of, and treated, as a lifestyle choice, nicotine is an addictive substance 
with similar potency to alcohol and opiates (US Department of Health and Human 
Services 1988). Nicotine dependence is a Substance Use Disorder in the Diagnostic Neuropsychiatric Disease and Treatment 2008:4(2) 354
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and Statistical Manual of Mental Disorders, Fourth 
Edition – Revised (DSM-IV-TR) (APA 2000) and ranks 
higher on scales of physical and psychological dependency 
than alcohol, amphetamines, and cannabis (Nutt et al 2007). 
Repeated self-administration of nicotine from cigarettes 
is due to nicotine’s effects on several neurotransmitters, 
including dopamine, released following nicotine’s stimula-
tion of central nicotinic acetylcholine receptors (nAChR) 
(Kelley 2002). In addition, withdrawal from nicotine results 
in a combination of psychological and physical symptoms 
leading to cravings and a continued desire to smoke (West 
et al 2006; Hughes 2007). These combined negative and 
positive reinforcing effects result in many smokers needing 
to make several quit attempts before successfully stopping 
smoking. The US Clinical Practice Guideline identiﬁ  es 
nicotine addiction as a “chronic condition”, and recom-
mends smokers be given social and medicinal support by 
physicians and health care workers in order to help them 
quit (Fiore et al 2000).
Background/history of treatments 
for smoking cessation
The recommended behavioral treatment for smoking ces-
sation is the type of cognitive behavioral therapy that 
emphasizes, among other things, motivation for stopping, 
smoking as a conditioned behavior, and alternative responses 
to craving and risk of relapse. Psychosocial treatments are 
recommended and provide additional efﬁ  cacy, although 
they are not necessary for pharmacotherapy to be effective. 
However, clinical trials assessing the efﬁ  cacy and safety of 
pharmacotherapies usually include brief counseling sessions 
in accordance with guidelines (Fiore et al 2000).
The ﬁ  rst effective drug available as a smoking cessation 
aid was nicotine gum which received approval from the US 
Food and Drug Administration (FDA) in 1984. Thereafter 
several formulations followed. Nicotine itself is not carci-
nogenic. The biological damage resulting from cigarette 
smoking is due to other toxic and carcinogenic agents found 
in cigarette smoke (Hoffmann et al 2001). Consequently, 
nicotine replacement therapy (NRT) provides nicotine 
without the other damaging chemicals administered via 
cigarette smoke. The principle of using NRT as a smoking 
cessation aid is to wean smokers off tobacco dependence by 
substituting the nicotine, and therefore reducing the craving 
for cigarettes and withdrawal symptoms after quitting. Each 
NRT treatment has been shown to approximately double the 
odds of remaining abstinent from smoking in comparison to 
placebo (Silagy et al 2004).
The ﬁ  rst non-nicotine drug to be introduced as a therapy 
for smoking cessation was sustained-release bupropion 
(bupropion SR) which was approved by the FDA for this use 
in 1997. Bupropion SR, a re-uptake inhibitor of dopamine 
and noradrenaline and a blocker of nicotine’s activation of 
several neuronal nAChRs (Slemmer et al 2000) was origi-
nally developed as an atypical antidepressant, but its efﬁ  cacy 
as a smoking cessation drug has been consistently shown in 
clinical trials. Bupropion SR also doubles the odds of suc-
cessful cessation 12 months after quitting in comparison to 
placebo (Hughes et al 2004).
Fortunately, the growing interest in the need to give up 
smoking has been paralleled by an interest from the phar-
maceutical industry to ﬁ  nd and develop additional and more 
effective drugs as smoking cessation aids. Some of these have 
failed to be approved for this use by the FDA. For example, 
rimonabant, a cannabinoid receptor antagonist, was identi-
ﬁ  ed as a potential pharmacotherapy for smoking cessation, 
due to the implicated role of the endocannabinoid system 
in nicotine dependence (Fagerström and Balfour 2006; 
Sui and Tyndale 2007). Rimonabant reduced nicotine self-
administration in rats (Cohen et al 2002) and also decreased 
the ability of cues to elicit nicotine use in rats (Cohen et al 
2005). However, a recent review of non-nicotinic therapies 
reported that rimonabant produced inconsistent results in 3 
Phase 3 smoking cessation trials (Sui and Tyndale 2007). 
Rimonabant was not approved by the FDA for smoking ces-
sation due to concerns about its psychiatric and neurologic 
adverse event (AE) proﬁ  le (FDA 2007a).
Other pharmacotherapies have been speciﬁ  cally devel-
oped for smoking cessation. Nicotine vaccines have been 
formed to prevent nicotine from entering the brain, thereby 
blocking nicotine’s effects (Fagerström and Balfour 2006; 
Sui and Tyndale 2007). While the safety of the current vac-
cines may not be a problem, early clinical trials cast some 
doubts over whether the vaccines will be effective enough 
to induce abstinence. Evidence from experiments with rats 
indicates that relapse prevention is probably a better indi-
cation for the vaccines unless good predictors of antibody 
response can be established before vaccination (Lindblom 
et al 2002). Another medication speciﬁ  cally developed for 
smoking cessation, varenicline, received FDA approval in 
2006. In this paper we will review this latest addition in the 
physicians’ armamentarium for helping smokers to quit.
Development of varenicline
Varenicline’s synthesis was informed by basic research 
revealing the structure and functional properties of nAChRs Neuropsychiatric Disease and Treatment 2008:4(2) 355
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and the effects of cytisine – a useful ligand for studying 
nAChRs (Pabreza et al 1991). Interestingly, cytisine has 
been historically used to help people stop smoking in Eastern 
Europe (Coe et al 2005; Etter 2006; Rollema et al 2007a).
The α4β2 nAChR is believed to have the highest sensitivity 
to nicotine (Benowitz et al 1989; Fenster et al 1997). Activa-
tion of these receptors in the ventral tegmental area occurs 
when sufﬁ  cient levels of nicotine are carried in the blood. The 
ventral tegmental area contains dopaminergic neurons which 
release dopamine via mesolimbic projections to the nucleus 
accumbens (Balfour 2004). Mice lacking either the α4 or 
β2 subunits of the nAChR did not show the usual increased 
dopamine levels in the mesolimbic system in response to 
nicotine administration (Picciotto et al 1999; Marubio et al 
2003). Consequently, these receptors are thought to play a 
mediating role in dopamine release following the intake of 
nicotine, which is in turn linked to nicotine’s reinforcing 
effects (Kelley 2002; Pidoplichko et al 2004; Foulds 2006). 
Based on these observations, the α4β2 receptor was identiﬁ  ed 
as a potential target for a smoking cessation drug, especially 
with a partial agonist at this receptor subtype (Rollema et al 
2007b). Varenicline was developed to have a high afﬁ  nity 
for α4β2 nAChR in the mesolimbic dopamine system (Coe 
et al 2005; Rollema et al 2007a) and to act as a selective 
partial agonist of the α4β2 nAChR. Like other partial ago-
nists (eg, buprenorphine), varenicline has both agonist and 
antagonist effects. Binding at α4β2 nAChR is hypothesized 
to increase the dopaminergic tonus in relevant brain areas 
which decreases the craving for nicotine and alleviates the 
symptoms of withdrawal (agonist effects). In addition, block-
ing of nicotine’s binding at these receptors is hypothesized to 
reduce nicotine-induced dopamine release and, consequently, 
its rewarding/reinforcing effects (antagonist effects) (Coe 
et al 2005; Rollema et al 2007a).
Pharmacology of varenicline
Evidence for varenicline’s hypothesized agonist/antagonist 
dual mechanism of action has been demonstrated in both 
in vivo and in vitro studies. In terms of agonist effects, in brain 
slices taken from rats, varenicline stimulated 40%–60% less 
dopamine release than nicotine, consistent with the effects 
of a partial agonist (Rollema et al 2007a). In rats that were 
successfully trained to discriminate between nicotine and a 
saline solution using a 2-lever food pellet-reinforced drug 
discrimination procedure, varenicline fully substituted for the 
nicotine cue. In terms of antagonist effects, when varenicline 
was administered before nicotine, dopamine release was less 
than with nicotine alone (Rollema et al 2007a). Finally, in a 
nicotine self-administration model, varenicline was shown 
to reduce nicotine intake. Responses to nicotine following 
a maximally effective dose of varenicline were reduced to 
a similar level as responses to saline solution (Rollema et al 
2007a). This could represent an antagonist effect, in which 
varenicline blocks the reinforcing effects of nicotine; or it 
could represent an agonist effect, in which varenicline serves 
as a substitute for nicotine (Rollema et al 2007a).
Varenicline has an elimination half-life of approximately 
24 hours (Faessel et al 2006). The maximum absorption of 
varenicline occurs within about 3  –4 hours following oral 
administration, and steady-state conditions are typically 
reached within 4 days following regular doses in healthy 
adults (Faessel et al 2006). Plasma concentrations and the 
pharmacokinetic parameters following the administration 
of varenicline were unaffected by the consumption of food 
and were similar for smokers and non-smokers (Faessel et al 
2006). Varenicline has a simple metabolic and excretory 
proﬁ  le in mice, rats, monkeys, and humans (Obach et al 
2006). In humans, less than 10% of varenicline is excreted 
as metabolites and approximately 92% of varenicline is 
excreted unchanged in urine, indicating that the major route 
of clearance for varenicline is renal excretion (Obach et al 
2006). Although their nAChR binding afﬁ  nities have not been 
reported, it is highly unlikely that metabolites contribute to 
the activity of varenicline, since they either lose the amine 
function required for binding to nAChRs, or are only present 
in urine (Obach et al 2006). If renal excretion is affected by 
kidney failure the dose can be decreased to 0.5 mg twice daily 
(bid) which has also been found to be more effective than 
placebo in healthy subjects (Oncken et al 2006).
Partial agonists have been shown to be less susceptible 
to abuse in comparison to their full-agonist counterparts 
(Jasinski et al 1978; Jasinski and Preston 1985; Busto et al 
1994). The subjective effects of varenicline signiﬁ  cantly dif-
fered from those of a prototypic stimulant with abuse potential 
(ie, amphetamine) and were consistent with the proﬁ  le of a 
drug with low abuse potential (McColl et al 2008). In addition, 
varenicline appears to be safe and well tolerated in healthy 
adults from 18 to 65 years of age (Gonzales et al 2006; Jorenby 
et al 2006; Nides et al 2006; Oncken et al 2006; Williams et al 
2007), and also in healthy adults over 65 years (Burstein et al 
2006). There are no contraindications with varenicline and 
no known drug interactions (Pﬁ  zer Ltd 2007).
Varenicline in clinical use
The efﬁ  cacy and safety of varenicline for smoking cessa-
tion has been assessed in Phase 2 and Phase 3 randomized Neuropsychiatric Disease and Treatment 2008:4(2) 356
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clinical trials. Results of 1 Phase 2 trial demonstrated that 
varenicline 1 mg in either once daily or bid doses increased 
the odds of quitting in comparison to placebo during a 7-week 
treatment period (6 weeks active drug followed by 1 week 
placebo) (Table 1). However, the continuous abstinence rate 
of the participants given varenicline 1 mg bid was greater 
than that of the 1 mg once daily varenicline group (Table 1) 
(Nides et al 2006). Another Phase 2 trial used both titrated 
and non-titrated dosing and also showed that varenicline 
resulted in signiﬁ  cantly more participants remaining con-
tinuously abstinent (Table 1) (Oncken et al 2006). In both 
studies, efﬁ  cacy was maintained through 1-year follow-up 
(Table 1) (Nides et al 2006; Oncken et al 2006).
In these Phase 2 trials the most common AEs experienced 
by varenicline participants were nausea, insomnia, abnormal 
dreams, and headaches (Nides et al 2006; Oncken et al 2006). 
These trials established that the optimal dosing of varenicline, 
while maintaining an acceptable safety proﬁ  le, was 1 mg bid 
up titrated during the ﬁ  rst week (Nides et al 2006; Oncken 
et al 2006) and that 12 weeks of drug treatment resulted in 
higher efﬁ  cacy rates than the 7-week treatment period (Nides 
et al 2006; Oncken et al 2006) and thus, this dosing schedule 
was used in the 2 identically-designed Phase 3 trials (0.5 mg 
per day for the ﬁ  rst 3 days, followed by 0.5 mg bid for 4 days, 
then 1 mg bid for the remainder of the 12 weeks).
In both these Phase 3 trials, participants were randomized 
to receive varenicline 1 mg bid, bupropion SR 150 mg bid, or 
placebo (1:1:1) (Gonzales et al 2006; Jorenby et al 2006).
Week 9–12 and Week 9–52 continuous abstinence 
rates were signiﬁ  cantly greater for varenicline than placebo 
in both trials (Table 2) (Gonzales et al 2006; Jorenby et al 
2006). Varenicline also achieved signiﬁ  cantly greater efﬁ  cacy 
over bupropion SR in Weeks 9–12 in both studies and this 
was maintained for Weeks 9–52 in 1 trial (Table 2) (Jorenby 
et al 2006). In the other trial, although the effect size was 
similar, this just missed statistical signiﬁ  cance (Table 2) 
(Gonzales et al 2006).
Safety analyses of pooled data based on the 2 Phase 3 
trials cited above (Gonzales et al 2006; Jorenby et al 2006) 
were conducted based on 2,045 subjects who received at least 
1 dose of study medication (varenicline, N = 692; bupropion 
SR, N = 669; or placebo, N = 684) (Nides et al 2008). Var-
enicline demonstrated an acceptable safety proﬁ  le. Nausea 
(29%), insomnia (14%), and headache (14%) were the most 
commonly reported AEs in the pooled varenicline data. A 29% 
nausea ﬁ  gure seems high and was greater than nausea events 
reported in the bupropion SR participants (10%) and placebo 
participants (9%) (Nides et al 2008). However, discontinuation 
from study treatment due to nausea was rare and occurred in 
3% of the varenicline participants, compared with 1% of the 
bupropion SR participants and less than 1% of the placebo 
group. Nausea has consistently been the most frequently 
reported AE by participants taking varenicline, although the 
majority of these nausea experiences were reported as mild to 
moderate in intensity (Gonzales et al 2006; Jorenby et al 2006; 
Nides et al 2006; Oncken et al 2006; Nakamura et al 2007; Tsai 
et al 2007; Williams et al 2007). Furthermore, the onset and 
incidence of nausea peaked in the second week of treatment 
and reduced thereafter (Nides et al 2008). Overall, discontinu-
ation from treatment for any reason occurred most frequently 
in the bupropion SR group (14%), followed by varenicline 
(10%), and then placebo (8%) (Nides et al 2008).
Table 1 Abstinence rates of Phase 2 studies
  CAR for any 4-week   End of treatment CAR   CAR Weeks 4–52  CAR Weeks 9–52
  period during the    Weeks 9–12
  7-week treatment phase
  Varenicline   Varenicline   Varenicline   Varenicline   Varenicline   Varenicline  Varenicline   Varenicline
  1 mg/day vs   1 mg bid vs   0.5 mg bid vs   1 mg bid vs   1 mg/day vs   1 mg bid vs   0.5 mg bid vs   1 mg bid vs
 placebo  placebo  placeboa placeboa placebo  placebo  placeboa  placeboa
Nides et al   37% vs 17%;   48% vs 17%;       6% vs 5%;   14% vs 5%;    
2006 (N = 638)  OR 2.97;   OR 4.71;       ns (p-value not   p  0.01
 p   0.001  p  0.001      provided in 
       publication)
Oncken et al       44% vs 12%;   49% vs 12%;       19% vs 4%;   22% vs 4%; 
2006 (N = 647)      OR 6.32;   OR 8.07;       p  0.001   p  0.001
     p   0.001  p  0.001      (OR not   (OR not
          provided    provided
          in  publication)  in  publication)
aPooled titrated and non-titrated treatment groups.
Abbreviations: CAR, continuous abstinence rate; OR, odds ratio.Neuropsychiatric Disease and Treatment 2008:4(2) 357
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Varenicline has been compared with NRT in 2 studies. A 
non-randomized study compared varenicline with various 
NRTs in a smokers’ clinic giving 7 group therapy ses-
sions in addition to the medicine in smokers with and 
without prior or current mental illnesses. The cessation 
rate at 6 weeks (the only time point reported) was higher 
with varenicline than that with the use of 1 NRT, 72% vs. 
61% (OR 1.7); however, varenicline did not result in a 
greater cessation rate than that established with the use of 
2 NRTs. There were signiﬁ  cantly more side effects with 
varenicline. The most common were nausea, disturbed 
sleep, vivid dreams, drowsiness, and constipation. Vareni-
cline was similarly effective in those with mental illness 
and showed no evidence of worsening mental illnesses 
(Stapleton et al 2008).
The second study analyzed outcomes of randomized and 
treated participants in an open-label comparison of vareni-
cline 1 mg bid (N = 376) with NRT, a 21 mg transdermal 
patch, (N = 370). Doses of NRT were 21 mg/day for the 
ﬁ  rst 6 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 
weeks. Continuous abstinence rate for the last 4 weeks of 
12 weeks of varenicline standard regimen treatment was 
signiﬁ  cantly greater than the continuous abstinence rate for 
the last 4 weeks of the standard regimen transdermal nicotine 
treatment, 56% and 43%, respectively (OR 1.70; p  0.001) 
(Table 2) (Aubin et al 2008). The effect size was relatively 
similar at 52 weeks, but not statistically signiﬁ  cant, 26% and 
20%, respectively (OR 1.40; p = 0.056) (Table 2) (Aubin 
et al 2008). In addition, varenicline showed a beneﬁ  t over 
transdermal nicotine on craving, withdrawal symptoms, 
and feelings of smoking satisfaction reduction (Aubin et al 
2008). Participants were aware of whether they had received 
NRT or varenicline and participants often believe that a 
new treatment or a prescription medication is superior to 
an older or over-the-counter medicine. How much of the 
superiority of varenicline was due to these expectancy 
effects is unknown.
Varenicline demonstrated an acceptable safety proﬁ  le, 
although there were more reported AEs in the varenicline 
group than the NRT group. The most frequent AE in the 
varenicline group was nausea (varenicline, 37%; NRT, 
10%), followed by insomnia (varenicline, 21%; NRT, 19%), 
and headache (varenicline, 19%; NRT, 10%) (Aubin et al 
2008). There was also 1 report of suicidal ideation in the 
varenicline group (Aubin et al 2008). The FDA and the 
European Medicines Agency (EMEA) have recently warned 
providers and users of varenicline to monitor changes in 
behavior and increase awareness of cases of suicidal ide-
ation and suicide attempts, due to some post-marketing 
reports of agitation, depressed mood, suicidal ideation and 
behavior in patients being treated with varenicline (EMEA 
2007; FDA 2007b). As yet, there is no conﬁ  rmed causal 
Table 2 Abstinence rates of varenicline versus active comparator trials
  End of treatment CAR  CAR through Week 52
  Varenicline   Varenicline 1   Bupropion SR   Varenicline 1  Varenicline 1  Varenicline 1   Bupropion   Varenicline
  1 mg bid vs   mg bid vs   150 mg bid vs   mg bid vs  mg bid vs  mg bid vs   SR 150 mg   1 mg bid vs
 NRT    placebob placebob bupropion  SR  NRT  placebod  bid vs   bupropion
  transdermal       150 mg bidb transdermal    placebod  SR 150 mg
 patcha        patchc     bidd
Gonzales    44% vs 18%;  30% vs 18%;  44% vs 30%;    22% vs 8%;  16% vs 8%;  22% vs 
et al 2006    OR 3.85;   OR, 2.00;  OR 1.93;     OR 3.09;   p = 0.001  16%;
(N = 1023)    p < 0.001  p < 0.001  p < 0.001    p < 0.001  (OR not   OR 1.46; 
              provided in   p = 0.057
            publication)
Jorenby     44% vs 18%;  30% vs 18%;   44% vs 30%;    23% vs 10%;  15% vs   23% vs 
et al 2006    OR 3.85;   OR 2.02;   OR 1.90;     OR 2.66;  10%; OR,   15%;
(N = 1022)    p < 0.001  p = 0.001  p < 0.001    p < 0.001  1.50;  OR 1.77; 
              p = 0.08  p = 0.004
Aubin et al   56% vs         26% vs 20%;     
2008  43%;      OR  1.40;       
(N = 746)  OR 1.70;         p = 0.056     
  p  <  0.001           
aEnd of treatment CAR = varenicline Weeks 9–12; NRT Weeks 8–11.
bEnd of treatment CAR = Weeks 9–12.
cLong-term CAR = varenicline Weeks 9–52; NRT Weeks 8–52.
dLong-term CAR = Weeks 9–52.
Abbreviations: CAR, continuous abstinence rate; NRT, nicotine replacement therapy; OR, odds ratio.Neuropsychiatric Disease and Treatment 2008:4(2) 358
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link between these symptoms and varenicline since stopping 
smoking by itself can in rare cases cause such symptoms 
(FDA 2007b).
The clinical trials discussed so far have included healthy 
adults from the Western world, the majority of whom were 
white. The efﬁ  cacy of varenicline over placebo has also 
been demonstrated in Asian participants. A study con-
ducted in Japan found that participants classiﬁ  ed as nicotine 
dependent and randomized to varenicline 1 mg bid achieved 
greater continuous abstinence rates for the last 4 weeks of 
a 12-week treatment phase than similar smokers random-
ized to receive placebo (Table 3) (Nakamura et al 2007). 
Superior efﬁ  cacy of varenicline was maintained through 
Weeks 9–52, following a 40-week non-treatment follow-
up period (Table 3) (Nakamura et al 2007). In Taiwan and 
Korea, participants in the varenicline group also obtained 
greater abstinence rates than placebo for Weeks 9–12 at the 
end of treatment (Table 3) (Tsai et al 2007) and through 
12 weeks of post-treatment follow-up (Table 3) (Tsai et al 
2007). No 52-week follow-up was conducted in this study. 
Both these Asian trials resulted in safety proﬁ  les similar to 
those reported in the Phase 3 studies conducted in the West 
(Gonzales et al 2006; Jorenby et al 2006; Nakamura et al 
2007; Tsai et al 2007).
Further trials assessing varenicline as a smoking cessation 
aid are underway in participants with cardiovascular disease 
(www.clinicaltrials.gov identiﬁ  er: NCT00282984) and chronic 
obstructive pulmonary disease (www.clinicaltrials.gov identi-
ﬁ  er: NCT00285012). Participants are being recruited to assess 
the effects of varenicline on mood in depressed outpatient 
smokers (www.clinicaltrials.gov identiﬁ  er: NCT00525837), to 
assess the effects of varenicline as an adjunct to schizophrenia 
(www.clinicaltrials.gov identiﬁ  er: NCT00492349), and to 
prompt quitting in ambivalent smokers (www.clinicaltrials.
gov identiﬁ  er: NCT00595868). A further trial is recruiting 
adolescents to assess the pharmacokinetic proﬁ  le following 
multiple doses of varenicline in this population (www.clini-
caltrials.gov identiﬁ  er: NCT00463918).
Degree of nicotine dependence 
and efﬁ  cacy of varenicline
Nicotine dependence, most often measured by the Fagerström 
Test for Nicotine Dependence (FTND), is a strong predic-
tor of abstinence, particularly in non-treated smokers (eg, 
Fagerström and Schneider 1989; Hyland et al 2004; Foulds 
et al 2006). Analysis of pooled data from the two Phase 3 
studies (Gonzales et al 2006; Jorenby et al 2006) examined 
abstinence according to baseline demographics of smok-
ing status (Nides et al 2008). Subgroups were classiﬁ  ed 
according to participant scores on the FTND (Heatherton 
et al 1991) (FTND scores of 0–3, 4–6, or 7–10); but also 
for number of cigarettes smoked per day (10 to 20, 20 
to 30, or 30); and the time to the ﬁ  rst cigarette of the 
day (30 min or 30 min after waking). These last two 
are the most important questions in the FTND. In each of 
these subpopulations, lower-dependence smokers had higher 
abstinence rates, and participants randomized to receive 
varenicline achieved higher abstinence rates than those 
randomized to receive bupropion SR or placebo (Figure 1). 
To determine whether the efﬁ  cacy of varenicline differed 
by degree of dependence, treatment by subgroup interac-
tions were examined and these were not signiﬁ  cant for daily 
cigarette consumption (p = 0.16), FTND score (p = 0.26), and 
time to ﬁ  rst cigarette of the day (p = 0.40) (Nides et al 2008). 
These results indicate that varenicline is effective regardless 
of the degree of nicotine dependence although efﬁ  cacy tends 
to decline as dependence increases.
Prior studies have found higher dependency is linked with 
lower success rates (Fiore et al 2000). One exception occurred 
in a nicotine nasal spray trial (Sutherland et al 1992). In this 
study, the heaviest smokers (assessed by plasma nicotine 
levels and dependence questionnaire responses at baseline) 
showed the greatest advantage of using the nicotine spray. 
While the likelihood of abstinence declined for the placebo 
group with increasing dependence, the rates of abstinence in 
the group given the active spray were similar, regardless of 
dependence level at baseline. With nicotine gum, the more 
Table 3 Abstinence rates in other studies
  CAR Weeks 9–12  CAR Weeks 9–24  CAR Weeks 9–52
  Varenicline 1 mg bid vs placebo  Varenicline 1 mg bid vs placebo   Varenicline 1 mg bid vs placebo
Nakamura et al  65% vs 40%  38% vs 30%  35% vs 23%
2007 (N = 515)  OR 2.98; p < 0.001  OR 1.47; p = 0.149  OR 1.81; p = 0.036
Tsai et al 2007   60% vs 32%   47% vs 22%  
(N = 250)  OR 3.22; p < 0.001  OR 3.38; p < 0.001 
Abbreviations: CAR, continuous abstinence rate; OR, odds ratio.Neuropsychiatric Disease and Treatment 2008:4(2) 359
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dependent subjects do better with a 4 mg strength than with 
a 2 mg strength (Tønnesen et al 2007).
This ﬁ  nding raises the question of whether a higher dose, 
or longer treatment period, with varenicline would increase 
the success rate of the heaviest dependent smokers and give 
them the same chance to succeed as the lower dependent 
smokers. A maintenance trial has already established that an 
extended period of treatment with varenicline does help to 
maintain abstinence compared with placebo (Tonstad et al 
2006). Participants who had successfully quit with vareni-
cline at the end of a 12-week open-label treatment period 
were randomized to receive a further 12 weeks of treatment 
with varenicline or placebo. This advantage for varenicline 
continued through Weeks 13–52 (44% vs 37%, respectively; 
OR 1.34; p = 0.02) (Tonstad et al 2006).
The maintenance trial also demonstrated an acceptable 
safety proﬁ  le for participants during the extended treatment 
period with varenicline (Tonstad et al 2006). A long-term 
safety trial has further demonstrated that varenicline 1 mg 
bid can be safely administered for up to 12 months (Williams 
et al 2007). Tolerability of varenicline was also shown to 
be acceptable following a single dose of 3 mg in smoking 
participants, while there was a decreased tolerability at this 
dose in non-smokers (Faessel et al 2006). This ﬁ  nding of 
increased tolerability to higher doses according to smoking 
status might imply that smokers with a heavier nicotine intake 
may also be more tolerant of higher doses than smokers with 
a lower nicotine intake or at least a higher dose could be 
contemplated in patients without side effects. As yet, analy-
ses directly testing the effect of extended or higher doses 
of varenicline treatment according to nicotine dependency 
level have not been conducted; however, the results would 
be interesting to observe.
How to manage nausea 
with varenicline
Incidents of nausea are less frequent with up-titrated, rather 
than non-titrated dosing (Oncken et al 2006) and symptoms 
of nausea may be reduced when varenicline is administered 
following food in comparison to fasted conditions (Faessel 
et al 2006). In clinical use, patients should be advised to 
take varenicline with food or at least water. However, if the 
recommended dose of varenicline is not tolerable, it may be 
necessary to reduce the dose (Pﬁ  zer Ltd 2007; Pﬁ  zer Inc 2008). 
The lower dose of varenicline 0.5 mg bid has also been shown 
to be signiﬁ  cantly more efﬁ  cacious than placebo at the end 
Figure 1 Percentage of varenicline and placebo participants achieving continuous abstinence at Weeks 9–12 and Weeks 9–52 according to nicotine dependence level (low/
med/high). Derived from data of Nides et al (2008).
Abbreviation: FTND, Fagerström Test for Nicotine Dependence.
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of treatment and through 52 weeks of follow-up (Table 1) 
(Oncken et al 2006). Future strategies for reducing nausea 
with varenicline may include alternative formulations to avoid 
oral administration, such as via a transdermal route.
Varenicline and positive or negative 
reinforcement for smokers
Nicotine addiction can be reinforced by nicotine’s ability to 
enhance vigilance, decrease anger and hunger, and improve 
cognitive function and mood (Benowitz 1996). However, 
drug reinforcement can also take the form of a reduction 
in negative effects from withdrawal such as restlessness, 
irritability, anxiety, tobacco craving, and insomnia, as well 
as reduced concentration levels (APA 2000).
These 2 types of reinforcement are crucial to understanding 
the complexity of nicotine addiction and how smoking behav-
ior is maintained (Henningﬁ  eld and Keenan 1993). Smokers 
might smoke predominantly for either positive reinforcement 
(to experience the positive effects during smoking) or negative 
reinforcement (to relinquish the negative symptoms of with-
drawal between cigarettes). Other terms for describing roughly 
the same phenomenon are “trough maintainers” and “peak seek-
ers” (Russell 1990). In addition, with increasing restrictions on 
smoking, continuing smokers may have moved from negative 
reinforcement to more positive reinforcement motives. The 
Michigan Nicotine Reinforcement Questionnaire was devised 
as a subjective measure of individual positive reinforcement 
and negative reinforcement for potential use as a diagnostic tool 
for individual intervention (Pomerleau et al 2003).
The ﬁ  rst author of this review has also tried to capture 
the type of reinforcement (negative reinforcement: NR, or 
positive reinforcement: PR) in 1 single question:
“ – If you have tried to stop smoking what was the most 
difﬁ  cult, choose A or B.
A.  The permanent state of something missing and that 
you did not function well (NR).
B.  That you could not smoke at those special moments 
when it really taste well and makes you feel good (PR).”
This question was used to ascertain the reinforcement 
type of 73 participants from 2 European centers (Fagerström 
et al 2007) in the maintenance trial of varenicline described 
earlier in this review (Tonstad et al 2006). Point prevalence 
abstinence rates at 6 months were signiﬁ  cantly higher for PR 
participants (77%) than for NR participants (52%; p  0.05) 
(Fagerström et al 2007). When abstinence data were analyzed 
in a 2 × 2 design (reinforcement type × high and low FTND 
score), the PR/low dependence group had a remarkably high 
abstinence rate of 85% in comparison to 68% of the PR/high 
dependence group. These data are shown in Figure 2, where 
they can be compared with the NR participants who showed 
lower success rates, with 58% in the low dependence group 
compared with 47% in the NR/high dependence group 
(Fagerström et al 2007) (Figure 2). These results indicate 
that varenicline may be more effective in helping smokers 
to quit when they have a low dependency on nicotine and are 
more inﬂ  uenced by the positive reinforcement of smoking 
than negative reinforcement factors. This interpretation of the 
data should be taken with caution due to the low number of 
participants included in these analyses; however, these results 
may provide justiﬁ  cation for further research in this area.
The modiﬁ  ed Cigarette Evaluation Questionnaire (mCEQ) 
evaluates subjective feelings of positive reward in participants 
who continue smoking and has been used to test the effects 
of varenicline on nicotine reinforcement. Varenicline partici-
pants in the Phase 3 trials also reported signiﬁ  cantly lower 
scores of smoking satisfaction (p  0.001), psychological 
reward (p  0.001), enjoyment of respiratory tract sensa-
tions (p  0.05), and craving reduction (p  0.05) than the 
placebo group on subscales of the mCEQ during periods of 
continued smoking (Gonzales et al 2006; Jorenby et al 2006). 
Comparisons of these measures averaged over Weeks 1–7 of 
the varenicline versus NRT trial also established that vareni-
cline signiﬁ  cantly reduced each of these positive subjective 
feelings in comparison to nicotine patches (p  0.001) (Aubin 
et al 2008). The effect size of varenicline versus placebo was 
at least twice as high as bupropion SR versus placebo on 
mCEQ scales for smoking satisfaction, psychological reward, 
and enjoyment of respiratory tract sensations (Gonzales et al 
2006). Together, these ﬁ  ndings provide support for the pro-
posed antagonist properties of varenicline (Coe et al 2005; 
Foulds 2006; Rollema et al 2007a).
Varenicline and tobacco withdrawal 
symptoms
Subjective measures of withdrawal experiences have been 
assessed with the Minnesota Nicotine Withdrawal Scale 
(MNWS) and The Brief Questionnaire of Smoking Urges 
(QSU-Brief) at baseline and at various other points during the 
trials (Gonzales et al 2006; Jorenby et al 2006). Consistent 
with the proposed agonist effects of varenicline (Coe et al 
2005; Foulds 2006; Rollema et al 2007a), varenicline partici-
pants reported signiﬁ  cantly lower urge to smoke (p  0.001), 
negative affect (p  0.001), and restlessness (p  0.05) on 
the subscales of the MNWS and signiﬁ  cantly lower craving 
scores on the QSU-Brief (p  0.001) in comparison to 
placebo in both the Phase 3 trials reported above (Gonzales Neuropsychiatric Disease and Treatment 2008:4(2) 361
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et al 2006; Jorenby et al 2006). The effect size of varenicline 
compared with placebo was also approximately double that 
of the effect size of bupropion SR compared with placebo 
for urge to smoke scores on the MNWS and craving scores 
on the QSU-Brief (Gonzales et al 2006).
Can varenicline be used to increase 
motivation and self-efﬁ  cacy?
The relevance of the proposed antagonist effects of vareni-
cline may be particularly pertinent to smokers with no interest 
in trying to quit, or who do not believe they are able to quit 
due to previously failed attempts. Reducing the rewarding 
effects of smoking may result in a reduced desire to continue 
smoking, or a desire to smoke less. Consequently, the dual 
mechanism of varenicline might mean that administering var-
enicline to such a group of ambivalent smokers could result 
in an increased motivation to cut down, or stop altogether 
due to its potential antagonist effects. Smokers with low, or 
no, motivation to stop smoking in the near future represent 
the majority of smokers (Wewers et al 2003). Therefore, if 
using varenicline can successfully motivate smokers to quit, 
the number of smokers who can beneﬁ  t from varenicline may 
be substantially increased.
Conclusions
Varenicline is a partial agonist at the α4β2 nAChR and is the 
latest FDA-approved smoking cessation drug to be added 
to physicians’ armamentarium. It has a straightforward 
pharmacokinetic proﬁ  le with low abuse potential, and 
has no known contraindications with other drugs. Two 
large randomized, placebo-controlled trials have shown 
varenicline to be signiﬁ  cantly more effective for smok-
ing cessation in comparison to placebo and bupropion SR 
in the short- and long-term. Varenicline also resulted in 
signiﬁ  cantly higher abstinence rates than NRT in the 1 
open-label study of NRT.
Varenicline has demonstrated an acceptable safety proﬁ  le 
for up to 1 year of treatment. Nausea is the most commonly 
experienced AE, but most experiences of nausea are of mild 
to moderate intensity and rarely cause drug discontinuation. 
The FDA and the EMEA have recently warned providers and 
users of varenicline to increase awareness of cases of suicidal 
ideation and suicide attempts, due to some post-marketing 
reports of changes of behavior in patients being treated with 
varenicline. As yet, there is no conﬁ  rmed causal link between 
these symptoms and varenicline.
The proposed dual agonist/antagonist mechanism of action 
of varenicline has been supported by participants’ subjective 
measures of experiences associated with smoking and smok-
ing withdrawal. As one would expect with agonist properties, 
varenicline reduced craving and symptoms of withdrawal in 
comparison to placebo, bupropion SR, and NRT. Consistent 
with the proposed antagonist effects of the drug, varenicline 
also reduced some of the rewarding aspects of smoking in 
comparison to placebo, bupropion SR, and NRT.
These promising results warrant further investigation 
into the clinical use of varenicline for smoking cessation. 
Potential areas for further research might include assessing 
the effects of varenicline for different types of smokers and 
for different motivation levels.
Such research would help physicians to give individual 
advice regarding the most effective pharmacologic aids for 
smoking cessation according to the needs of the smoker.
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